Why the study?
Does granulocyte-colony stimulating factor and autologous bone marrow-derived stem/progenitor cells improve cardiac function in patients with dilated cardiomyopathy?
Does granulocyte-colony stimulating factor and autologous bone marrow-derived stem/progenitor cells improve cardiac function in patients with dilated cardiomyopathy?
This paper describes the design of the REGENERATE-DCM trial, which aims to evaluate the efficacy of autologous bone marrow-derived stem cells and G-CSF in improving cardiac function in patients with dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
REGENERATE-DCM protocol enables testing of autologous stem cells plus G-CSF in dilated cardiomyopathy; leaves open whether this improves cardiac function.
The field of autologous stem/progenitor cell therapy for cardiovascular diseases has moved rapidly from bench to bedside. In particular, a small number of pilot studies have demonstrated the safety and efficacy of this treatment in dilated cardiomyopathy (DCM), but this has to be validated in large randomized trials. Here we introduce the Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial, which to our knowledge, is the first randomized, double-blind, placebo-controlled trial worldwide to investigate the role of granulocyte-colony stimulating factor and autologous bone marrow-derived stem/progenitor cells to improve cardiac function in patients with DCM.
No takes yet. Share an insight, caveat, or question.
Arnous et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: